Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

XtalPi Holdings Limited
晶泰控股有限公司

(formerly known as "QuantumPharm Inc.")
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2228)

INSIDE INFORMATION

This announcement is made by XtalPi Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to the Inside Information Provisions (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) and Rule 13.09 of the Listing Rules.

The board of directors of the Company (the "**Board**") wishes to inform the shareholders and potential investors of the Company that, based on a preliminary assessment of the information currently available to the Board, including the unaudited management accounts of the Group, the Group expects its revenue in the year ended 31 December 2024, as generated from the provision of (i) drug discovery solutions and (ii) intelligent automation solutions, would reach the revenue threshold of a Commercial Company (as defined under Chapter 18C of the Listing Rules), being HK$250,000,000. Such revenue had been due to the Group's business developments and market opportunities during the year ended 31 December 2024.

The Company is still in the process of preparing the annual results of the Group for the year ended 31 December 2024. The information contained in this announcement is only based on a preliminary assessment by the management of the Company with reference to the information currently available including the unaudited management accounts of the Group, which have not been reviewed or audited by the Company's auditors or the audit committee of the Company, and the actual results of the Group for the year ended 31 December 2024 may be different from what is disclosed herein. Investors are advised to read carefully the Group's annual results for the year ended 31 December 2024 which are expected to be published in due course pursuant to the requirements of the Listing Rules.

As at the date of this announcement, the Company is still regarded as a Pre-Commercial Company (as defined in Chapter 18C of the Listing Rules). The Company will make further announcements in due course in the event that the Company is notified by the Stock Exchange that it will no longer be regarded as a Pre-Commercial Company (as defined in Chapter 18C of the Listing Rules). Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
XtalPi Holdings Limited
Dr. Wen Shuhao
Chairman of the Board and Executive Director

Hong Kong, 17 February 2025

As at the date of this announcement, the Board comprises Dr. Wen Shuhao, Dr. Ma Jian, Dr. Lai Lipeng and Dr. Jiang Yide Alan as executive Directors, and Mr. Law Cheuk Kin Stephen, Ms. Chan Wing Ki and Mr. Chow Ming Sang as independent non-executive Directors.